Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Exclusion Criteria

• •1. Patients with cerebrospinal membrane metastases;
• •2. Patients with acute/subacute hemorrhagic metastasis;
• •3. Inadequate organ function: 1) Blood tests: ANC ≤ 1.5 x 10\^9/L, PLT ≤ 90 x 10\^9/L, Hb ≤ 90g/L; 2) Blood biochemistry tests: TBIL ≥ 1.5 times the upper limit of normal; 3) ALT and AST ≥ 2.5 times the upper limit of normal;
• •4. Presence of serious and/or uncontrolled comorbidities that may affect participation: 1) allergy to study medications or adjuvant materials; 2) history of immunodeficiency, including HIV-positive or other acquired or congenital immunodeficiency diseases; 3) serious concomitant illnesses;
• •5. Pregnant and lactating female patients; female patients of childbearing age who are unwilling to use effective contraception during the trial period;
• •6. Patients who are unable to complete enhanced contrast MRI;
• •7. Patients who have been treated with Sacituzumab Govitecan and are resistant to the drug;
• •8. Any other condition that, in the opinion of the investigator, makes the patient ineligible for study participation.